title: Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC).
abstract: Immunomodulatory agents that target PD-1 and its ligand (PD-L1) are being increasingly used in the management of lung cancer. Potential immune-related adverse events include dermatological complications which mostly are of low grade severity. The use of immune checkpoint inhibitors may lead to the exacerbation of autoimmune conditions. We report a case of a documented psoriasis flare with anti-PD-1 treatment for lung cancer.
authors.affiliation: *Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre †The Olivia Newton-John Cancer Research Institute (ONJCRI), Austin Health ‡School of Cancer Medicine, La Trobe University, Vic., Australia.
authors.forename: Puey Ling
authors.initials: PL
authors.lastname: Chia
authors.forename: Thomas
authors.initials: T
authors.lastname: John
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000276:immunology; D002117:Calcitriol / Q000031:analogs & derivatives / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D000073865:Cigarette Smoking; D018450:Disease Progression; D066246:ErbB Receptors / Q000235:genetics*; D005091:Exons / Q000235:genetics; D006801:Humans; D008297:Male; D000068656:Mometasone Furoate / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D010789:Phototherapy; D011565:Psoriasis / Q000209:etiology / Q000517:prevention & control*; D017384:Sequence Deletion / Q000235:genetics
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; D000068656:Mometasone Furoate; C055085:calcipotriene; D066246:ErbB Receptors; D002117:Calcitriol